INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Feb 15, 2008 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 100 | $7.91 | 690 |
| Feb 15, 2008 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 100 | $7.91 | 690 |
| Feb 16, 2007 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 100 | $9.88 | 690 |
| Feb 24, 2020 |
Director
Trans History: 466
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 1,956 | $419.00 | 687 |
| May 07, 2020 |
Director
Trans History: 44
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 609 | $568.37 | 656 |
| Nov 25, 2014 |
Director
Trans History: 60
|
Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 400 | $410.00 | 655 |
| Nov 13, 2020 |
Director
Trans History: 48
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 11 | $345.47 | 654 |
| Jun 19, 2020 |
Director
Trans History: 65
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 2,548 | $630.01 | 654 |
| Feb 16, 2007 |
Director
Trans History: 282
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 62 | $9.88 | 652 |
| Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
Trans History: 660
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,400 | -- | 648 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.